Rapport Therapeutics reported net income of -$57.38M for the quarter ended Jun 2026. This income statement covers 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.44M | 1.53M | 1.51M | 2.05M | 10.67M | 36.58M | 20.74M | 36.50M | 36.50M | 37.93M | 38.93M | 47.81M | 47.96M |
| Revenue & cost | |||||||||||||
| Revenue | 20.00M | ||||||||||||
| Operating items | |||||||||||||
| Research & DevelopmentR&D | 4.72M | 7.58M | 11.80M | 12.50M | 15.69M | 15.54M | 17.20M | 19.57M | 22.68M | 22.28M | 30.26M | 32.72M | 51.41M |
| Selling, General & AdministrativeSG&A | 1.91M | 1.98M | 3.00M | 4.59M | 5.11M | 6.10M | 6.32M | 7.54M | 6.82M | 7.71M | 8.25M | 11.50M | 9.39M |
| Operating ExpensesOpex | 6.63M | 9.56M | 14.79M | 17.09M | 20.80M | 21.64M | 23.52M | 27.11M | 29.50M | 29.99M | 38.51M | 44.22M | 60.81M |
| Operating IncomeOp. Inc | -6.63M | -9.56M | -14.79M | -17.09M | -20.80M | -21.64M | -23.52M | -27.11M | -29.50M | -29.99M | -38.51M | -24.21M | -60.81M |
| EBIT | -6.63M | -9.56M | -14.79M | -17.09M | -20.80M | -21.64M | -23.52M | -27.11M | -29.50M | -29.99M | -38.51M | -24.21M | -60.81M |
| Non-operating items | |||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.22M | 0.86M | 1.38M | 1.81M | 2.68M | 4.10M | 3.54M | 3.04M | 2.76M | 3.06M | 4.75M | 4.36M | 4.19M |
| Non Operating IncomeNon Op. Inc. | 0.22M | 0.86M | 1.28M | -5.58M | 2.68M | 4.10M | 3.54M | 3.04M | 2.76M | 3.06M | 4.75M | 4.36M | 4.19M |
| Net income details | |||||||||||||
| EBT | -6.41M | -8.71M | -13.51M | -15.28M | -18.12M | -17.54M | -19.98M | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Tax ProvisionsTaxes | 0.00M | 0.00M | 0.01M | ||||||||||
| Profit After TaxPAT | -6.41M | -8.71M | -13.53M | -22.67M | -18.12M | -17.54M | -20.51M | -24.06M | -26.73M | -26.93M | -33.78M | -19.86M | -57.38M |
| Income from Continuing OperationsIncome (Continuing) | -6.41M | -8.71M | -13.52M | -15.28M | -18.12M | -17.54M | -19.98M | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Consolidated Net IncomeConsol Net Inc. | -6.41M | -8.71M | -13.52M | -15.28M | -18.12M | -17.54M | -19.98M | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Income towards Parent CompanyParent Net Inc | -6.41M | -8.71M | -13.52M | -15.28M | -18.12M | -17.54M | -19.98M | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Net Income towards Common StockholdersNet Income | -6.41M | -8.71M | -13.52M | -22.67M | -18.12M | -17.54M | -19.98M | -24.06M | -26.73M | -26.93M | -33.76M | -19.86M | -56.62M |
| Additional items | |||||||||||||
| EPS (Basic) | -4.45 | -5.70 | -8.98 | -11.07 | -1.70 | -0.50 | -0.96 | -0.68 | -0.75 | -0.71 | -0.87 | -0.42 | -1.19 |
| EPS (Diluted) | -4.45 | -5.70 | -8.98 | -11.07 | -1.70 | -0.50 | -0.96 | -0.68 | -0.75 | -0.71 | -0.87 | -0.42 | -1.19 |
| Shares Outstanding | 1.44M | 1.53M | 1.51M | 2.05M | 10.67M | 34.86M | 20.74M | 35.27M | 35.44M | 37.93M | 38.93M | 47.24M | 47.47M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.44M | 1.53M | 1.51M | 2.05M | 10.67M | 34.86M | 20.74M | 35.27M | 35.44M | 37.93M | 38.93M | 47.24M | 47.47M |
| EBITDA | -6.63M | -9.56M | -14.79M | -17.09M | -20.80M | -21.64M | -23.52M | -27.11M | -29.50M | -29.99M | -38.51M | -24.21M | -60.81M |
| Tax Rate | -0.03 | -0.01 | -0.04 |